الفهرس 
Myopic Choroidal Neovascularization.Only 14 pages are availabe for public view
 |  | from | 111 |  |  |
| | | from | 111 | | |
Abstract
Myopia is a common disorder estimated to affect approximately 1.6 billion people worldwide. This disorder is becoming by time prevalent, and it is estimated that up to 2.5 billion people will be affected. It is defined as a refractive condition in which the image of a distant object is formed anterior to the retina of the unaccommodated (relaxed) eye. Hine classified myopia by degree (low, medium, or high).
Pathologic myopia (PM) is defined as eyes having atrophic changes equal to or more severe than diffuse atrophy. Pathologic myopia is an important cause of visual impairment. Development of myopic Choroidal neovascularization (CNV) is one of the most common complications that lead to central vision loss in patients with pathologic myopia. If left untreated, it can cause scarring with expanding macular atrophy leading to irreversible visual loss in a period as short as 5 years.
Vascular endothelial growth factor (VEGF) has an important role appeared in mobilization of endothelial progenitor cells from the bone marrow to distant sites of neovascularization. The targeting of VEGFA as an essential regulator of both normal and pathological angiogenesis has revealed advanced therapeutic approaches in oncology and ophthalmology.
Optical coherence tomography (OCTA) angiography is one of the first non-invasive imaging techniques capable of detecting changes in the foveal avascular zone. Use of OCT angiography in everyday clinical practice allows for the accurate analysis of the chorioretinal vascular situation, with the identification of new vessels that could remain misdiagnosed. So, the aim of the study was the Evaluation of anti–vascular endothelial growth factor therapy in myopic choroidal neovascularization using optical coherence tomography angiography by detecting the changes of shape, size, and flow area.
Discussion
66
To elucidate our aim, this prospective study was conducted on (22) myopic eyes at (20) patients who are referred to the ophthalmologic clinic, faculty of medicine, Menoufia University. from May 2021 to April 2022.
All patients were subjected to the following:
Initially patients were underwent a detailed ophthalmological examination at baseline including: The best-corrected visual acuity (BCVA) of Snellen chart, Dilated fundus examination by indirect ophthalmoscope and Color fundus photography.
Best-corrected visual acuity was converted to the logarithm of the minimum angle of resolution (log MAR), Central macular thickness (CMT), greatest linear dimension (GLD) of CNV, subretinal fluid (SRF), and intraretinal fluid (IRF) before and after injection.
The results of this study could be summarized as follow:
Age of the studied patients ranged from 20-76 years with mean 52.53± 19.32 years and females were the most common among the studied patients (55%).
Medusa found in 8 patients (40%), sea fan found in 10 patients (50%), Indistinct found in 10 patients (50%) and dark halo found in 3 patients (15%).
There were not significantly differences among the studied groups regarding best-corrected visual acuity before and after Treatment with intravitreal ranibizumab (P=0.162).
Central macular thickness was significantly decreased after treatment with intravitreal ranibizumab than before treatment, with mean difference 45.55±71.27 (9.62%), (P=0.010).
Intraretinal fluid, subretinal fluid were significantly decreased after treatment with intravitreal ranibizumab than before treatment with changes 22.11% and 16.21%, respectively (P<0.05).
Discussion
67
Greatest linear dimension did not show any significant differences before and after treatment with intravitreal ranibizumab (P=0.524).
Flow area did not show any significant differences before and after treatment with intravitreal ranibizumab (P>0.05).